Evaluating the Effect of Sofosbuvir in COVID-19 Outpatients
Author Information
Author(s): Haddadzadeh Shoushtari Maryam, Raji Hanieh, Borsi Seyed Hamid, Tavakol Heshmatollah, Cheraghian Bahman, Moeinpour Mahtab
Primary Institution: Ahvaz Jundishapur University of Medical Sciences
Hypothesis
Can sofosbuvir effectively reduce symptoms and hospitalization in outpatients with mild COVID-19?
Conclusion
Sofosbuvir alone cannot significantly improve the treatment outcomes for outpatients with mild COVID-19.
Supporting Evidence
- The study involved 360 patients with mild COVID-19.
- Patients were randomly assigned to receive either sofosbuvir or a placebo.
- Results showed no significant differences in symptom duration or hospitalization rates between the two groups.
Takeaway
This study looked at whether a medicine called sofosbuvir helps people with mild COVID-19 feel better faster, but it didn't really make a difference.
Methodology
This was a randomized clinical trial with 360 patients divided into intervention and control groups, assessing symptoms and hospitalization after treatment with sofosbuvir or placebo.
Potential Biases
The study was triple-blind to minimize bias, but potential biases in patient selection and reporting could still exist.
Limitations
The study only included outpatients with mild COVID-19, which may limit the generalizability of the findings to more severe cases.
Participant Demographics
Participants were outpatients with mild COVID-19, with a mix of genders and ages ranging from 18 to 70 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website